---
title: "Prothena Corporation plc Publishes Presentation on Advancements in Life-Saving Therapies for Protein Dysregulation Diseases"
description: "Prothena Corporation plc has published a presentation on its advancements in developing therapies for protein dysregulation diseases, including Alzheimer's and Parkinson's. The presentation details th"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/241692599.md"
published_at: "2025-05-24T00:21:09.000Z"
---

# Prothena Corporation plc Publishes Presentation on Advancements in Life-Saving Therapies for Protein Dysregulation Diseases

> Prothena Corporation plc has published a presentation on its advancements in developing therapies for protein dysregulation diseases, including Alzheimer's and Parkinson's. The presentation details their focus on therapeutics that eliminate pathogenic proteins while preserving normal biology, featuring multiple clinical programs, including partnered Phase 2 and a wholly-owned Phase 1 program. Prothena collaborates with Bristol Myers Squibb, Novo Nordisk, and Roche, highlighting the global impact and economic burden of neurodegenerative diseases.

Prothena Corporation plc has released a presentation detailing its ongoing efforts in developing life-saving therapies for diseases related to protein dysregulation, such as Alzheimer's disease, Parkinson's disease, and transthyretin amyloidosis. The presentation highlights the company's focus on therapeutics engineered to eliminate pathogenic proteins while preserving normal biology, utilizing a biology-directed engine for disease-driven antibody engineering. It outlines multiple clinical programs, including three partnered Phase 2 programs and one wholly-owned Phase 1 program. Prothena has established strong collaborations with partners like Bristol Myers Squibb, Novo Nordisk, and Roche. The presentation also emphasizes the global impact of neurodegenerative diseases and the economic burden they pose. You can access the full presentation through the link below.

### Related Stocks

- [PRTA.US - Prothena](https://longbridge.com/en/quote/PRTA.US.md)
- [BMY.US - Bristol Myers Squibb](https://longbridge.com/en/quote/BMY.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Prothena Corp Q4 Earnings Assessment | Prothena Corp (NASDAQ:PRTA) reported its Q4 earnings on February 19, 2026, beating estimates by 11.11% with an EPS of $- | [Link](https://longbridge.com/en/news/276379367.md) |
| Prothena (NASDAQ:PRTA) Announces Earnings Results | Prothena (NASDAQ:PRTA) announced its quarterly earnings, reporting an EPS of ($0.40), exceeding analysts' expectations o | [Link](https://longbridge.com/en/news/276380011.md) |
| Fed's Kashkari: Hassett comments about Fed researchers represent another attack on independence | Minneapolis Fed president Neel Kashkari criticized comments from Trump administration economic adviser Kevin Hassett, wh | [Link](https://longbridge.com/en/news/276350286.md) |
| Hassett says New York Fed staff should be disciplined over study finding Americans paid for Trump's tariffs | Kevin Hassett, a White House economist, criticized a Federal Reserve Bank of New York study claiming that nearly 90% of  | [Link](https://longbridge.com/en/news/276253470.md) |
| Top BorgWarner Insiders Quietly Cash Out in Significant Stock Move | BorgWarner (BWA) experienced significant insider selling on February 19, 2026, with EVP Tonit Calaway selling 9,725 shar | [Link](https://longbridge.com/en/news/276412602.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.